CIK细胞序贯化疗药物腹腔灌注治疗晚期癌性腹水疗效观察

目的:探讨CIK细胞联合免疫调节剂治疗恶性肿瘤晚期腹水的效果.方法:选取50例中晚期肝癌、胃癌及胰腺癌合并腹水病人,随机分为顺铂组和CIK组各25例,顺铂组病人常规腹腔化疗(顺铂+甘露聚糖肽);CIK组病人采用腹腔内CIK细胞输注治疗,同时辅以甘露聚糖肽调节免疫,2次/周,共治疗8次.比较2组疗效、不良反应和相关指标及KPS评分.结果:50 例病人均完成治疗,CIK组病人总有效率为76.0％,明显高于顺铂组的40.0％(P<0.01).顺铂组不良反应主要为胃肠道反应和骨髓抑制,均可耐受;CIK组除1例出现一过性体温升高外,无其他不良反应发生.CIK组病人白细胞、白蛋白指标和食纳及KPS评分改善均明显优于顺铂组(P<0.01).结论:CIK免疫细胞治疗对控制恶性肿瘤晚期的腹水、改善病人症状有较好效果,且不良反应轻微,值得临床应用.

Effect of intraperitoneal CIK cell therapy in the treatment of malignant ascites

Objective:To observe the effects of the intraperitoneal cytokine-induced-killer(CIK)cell combined with immunomodulator in the treatment of malignant ascites.Methods:Fifty middle and advanced stage patients with liver,stomach and pancreas complicated with ascites were randomly divided into the DDP(cisplatin)group and CIK group(25 cases each group).The DDP group were treated with intraperitoneal DPP chemotherapy,and the CIK group were treated with CIK cell therapy combined with mannatide immunity regulating,twice a week for 8 times.The efficacy,adverse reaction and Karnofsky Performance Status(KPS)score between two groups were compared.Results:The total effective rate in CIK group(76.0％)was significantly higher than that in DDP group(40.0％)(P<0.01).The gastrointestinal disorder and bone marrow suppression were the main adverse reactions in DDP group.Except a case with transient body temperature increasing,no adverse reaction was found in CIK group.The improvement of white blood cells,albumin,appetite and KPS score in CIK group were significantly better than those in DDP group(P<0.01).Conclusions:The intraperitoneal CIK cell therapy can control the malignant ascites and improve the symptom of patients,which is little adverse reaction,and worthy of promotion in clinic.